Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378006 | 0.86 | HTR2C (0.62) | HTR2CSLC18A3SIGMAR1QDPRHTR6 | |
| Trifluoroacetic Acid SCHEMBL8528751 | 0.85 | SLC18A3 (0.69) | HTR2CSLC18A3SIGMAR1HTR6 | |
| Hydrochloric Acid SCHEMBL1765281 | 0.85 | HTR2C (0.64) | HTR2CSLC18A3SIGMAR1QDPRHTR6 | |
| Trifluoroacetic Acid SCHEMBL1870349 | 0.80 | HTR2C (0.50) | HTR2CSLC18A3SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL5671633 | 0.78 | OPRL1 (0.49) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL29921143 | 0.77 | PDE4A (0.43) | — | |
| SCHEMBL3648147 | 0.77 | DRD2 (0.51) | HTR2CSLC18A3SIGMAR1HTR1ASLC6A2 | |
| SCHEMBL31159074 | 0.77 | DRD2 (0.51) | HTR2CSLC18A3SIGMAR1HTR1ASLC6A2 | |
| SCHEMBL13975332 | 0.77 | DRD2 (0.51) | HTR2CSLC18A3SIGMAR1HTR1ASLC6A2 | |
| SCHEMBL31158728 | 0.77 | DRD2 (0.51) | HTR2CSLC18A3SIGMAR1HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3784234-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | HTR2C 1250/4885SLC18A3 54/4885SIGMAR1 1839/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | HTR2C 1250/4885SLC18A3 54/4885SIGMAR1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.